within Pharmacolibrary.Drugs.ATC.L;

model L04AG14
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.277 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 450 / 1000000,
    adminCount     = 1,
    Vd             = 0.00365,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Ublituximab is a chimeric anti-CD20 monoclonal antibody developed for the treatment of relapsing forms of multiple sclerosis (MS). It works by depleting B cells, which play a role in the pathogenesis of MS. Ublituximab is approved for the treatment of relapsing forms of MS.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adults with relapsing multiple sclerosis based on typical monoclonal antibody characteristics and public regulatory documents.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AG14;
